NEW YORK, NY — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational...
Latest News
Biomarker data suggest that NurOwn drives significant changes on multiple biomarkers across ALS disease pathways which may be important in achieving clinical outcomes NEW YORK – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will be...
A brave baby who recently had both kidneys removed was left fighting for life after developing a serious chest infection. Twenty-month-old Ella Chadwick underwent the radical surgery in April as her only hope of survival against the rare Congenital Nephrotic Syndrome, a potentially fatal disorder that affects one in 10,000...
São Paulo, Brazil – A technology originally designed for spraying crops with biological pest control products can be used in urban environments to reduce proliferation of insects that carry viruses harmful to humans, such as the mosquito Aedes aegypti, which transmits dengue, yellow fever, zika and chikungunya. Developed by BirdView,...
PHILADELPHIA, PA and VANCOUVER, British Columbia — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. GMP manufacturing of...
Chapel Hill, North Carolina – Despite affecting millions worldwide, Alzheimer’s disease (AD) has long lacked effective treatments due to a fundamental inadequacy of our understanding of its etiology and pathogenesis. The absence of an integrative theory connecting the molecular origins of AD with disturbances at the organelle and cell levels,...
Göttingen, Germany – In a study with 991 adults, scientists at DZNE show that the most common forms of frontotemporal dementia (FTD) as well as the neurological diseases amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP) can be recognised by blood testing. Their procedure is not yet ready for...
London, UK – A new study led by researchers at UCL and the University of Sheffield, has demonstrated the potential of stem cell therapy to treat those with Hirschsprung disease. Hirschsprung disease is a rare condition where some nerve cells are missing in the large intestine. This means the intestine...
Scientists have found success in treating a ‘neglected’ inflammatory condition, polymyalgia rheumatica, with a drug that could provide an alternative to steroids for patients. The study, carried out by Anglia Ruskin University (ARU) and published in the New England Journal of Medicine, describes a successful trial of sarilumab. The drug,...
Amsterdam – After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of not just one, but two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes...